current
epidem
involv
virus
deriv
singl
lineag
ha
within
lineag
four
distinct
clade
identifi
major
threat
public
express
recombin
trimer
ectodomain
ha
one
virus
strain
clade
insect
supplementari
fig
immobil
plastic
surfac
select
ab
nonimmun
human
ab
phage
display
librari
util
singlechain
vhvl
fragment
scfv
two
round
pan
screen
clone
identifi
uniqu
ab
form
six
distinct
vh
variabl
region
heavi
chain
fragment
combin
seven
differ
vl
variabl
region
light
chain
fragment
supplementari
tabl
found
nab
bound
trimer
similar
avid
bind
monomer
fig
present
scfvfc
construct
potent
neutral
clade
pseudoviru
fig
stringent
plaquereduct
assay
exhibit
high
level
neutral
well
diverg
clade
cd
found
nab
crosscompet
competit
elisa
supplementari
fig
suggest
share
common
epitop
base
find
well
vh
sequenc
divers
neutral
potenc
convert
three
nab
fulllength
human
studi
three
bound
recombin
high
affin
pm
slow
dissoci
rate
kd
supplementari
fig
protect
efficaci
three
viru
infect
evalu
balbc
mous
model
fig
mice
treat
prophylact
therapeut
lethal
viral
challeng
prophylaxi
use
mg
effect
protect
mice
challeng
high
lethal
dose
clade
clade
fig
therapeut
treatment
mg
achiev
dose
human
postinocul
also
protect
mice
challeng
either
viru
fig
mice
treat
later
time
postinocul
show
similar
higher
level
protect
fig
furthermor
surviv
mice
remain
healthi
show
minim
bodi
weight
loss
observ
period
data
shown
human
influenza
virus
typic
restrict
upper
respiratori
tract
system
spread
typic
outcom
infect
mice
report
human
found
three
caus
potent
suppress
viral
replic
lung
measur
day
postchalleng
mice
treat
within
hour
viral
challeng
two
effect
given
hpi
impact
antibodi
therapi
system
infect
dramat
demonstr
suppress
viru
spread
spleen
even
given
hpi
supplementari
fig
suppress
also
seen
brain
case
system
spread
low
control
anim
accur
quantit
two
way
antiha
ab
neutral
infect
block
initi
bind
ha
cellular
receptor
sialic
acid
interf
subsequ
step
hamedi
virushost
membran
fusion
occur
acid
found
none
nab
inhibit
viru
bind
cell
fig
hemagglutin
red
blood
cell
data
shown
howev
abl
show
use
model
system
cell
fusion
nab
potent
inhibit
membran
fusion
fig
order
provid
structur
basi
neutral
explor
prospect
develop
even
broaderspectrum
therapeut
determin
crystal
structur
scfv
fragment
complex
ectodomain
fig
supplementari
tabl
use
activ
cleavag
singl
chain
precursor
two
polypeptid
cleavag
lead
partial
burial
fusion
peptid
first
residu
also
contribut
format
three
hydrophob
pocket
locat
larg
trimer
receptorbind
head
complex
one
nab
bind
pocket
buri
protein
surfac
heavi
chain
vh
particip
directli
bind
util
three
complementaritydetermin
region
cdr
light
chain
vl
point
solut
make
nonspecif
contact
distal
end
oligosaccharid
glycosyl
residu
neighbor
monom
epitop
encompass
entir
pocket
form
fusion
peptid
flank
element
one
side
helix
key
interact
follow
fig
adopt
type
rel
rare
human
ab
two
hydrophob
residu
tip
insert
pocket
lie
across
flat
hydrophob
surfac
form
mainchain
fusion
peptid
residu
also
make
favor
orthogon
aromat
sidechain
back
pocket
front
subscript
refer
number
scheme
follow
structur
sulfur
make
iiaromat
ring
hydrophob
interact
helix
hbond
co
sidechain
ii
extend
apex
loop
locat
complement
cement
togeth
fusion
peptid
via
mainchain
hbond
helix
intercal
larg
hydrophob
residu
neighbor
posit
support
sidechain
conform
iii
loop
character
small
hydrophobicpolar
sidechain
notabl
thr
fit
snugli
beneath
ha
head
pack
helix
somat
mutat
conserv
glu
gener
noncanon
conform
point
outward
make
contact
ntermin
hairpin
residu
counterclockwis
neighbor
pack
side
helix
point
wrap
around
fusion
peptid
lock
place
fig
thu
may
stabil
fusion
peptid
one
subunit
one
framework
residu
appear
especi
import
stabil
loop
conform
form
hbond
main
chain
co
group
well
sidechain
residu
posit
major
determin
choic
two
distinct
conform
consist
structur
data
mutat
three
residu
make
import
interact
greatli
reduc
ablat
nab
bind
conserv
mutat
effect
fig
mutat
surfac
helix
either
effect
typic
expos
residu
lead
increas
nab
bind
perhap
subtli
increas
flexibl
epitop
fig
significantli
nine
nab
show
similar
mutant
bind
profil
togeth
crosscompetit
note
strongli
suggest
epitop
nab
overlap
close
inde
nab
bind
similar
locat
orient
broad
neutral
behavior
may
attribut
part
exclus
role
vh
antigen
bind
use
common
germlin
gene
five
six
vh
although
loop
variabl
sequenc
length
residu
supplementari
fig
supplementari
tabl
addit
free
energi
point
domin
bind
contribut
total
favor
free
energi
three
conserv
residu
vh
segment
fig
deriv
germlin
posit
alway
phe
posit
alway
hydrophob
milv
nab
alway
tyr
predict
lie
tip
loop
conserv
posit
conform
sequenc
loop
seem
critic
sinc
ab
isol
contain
somat
mutat
glu
found
predict
canon
structur
sixth
vh
gene
isol
deriv
germlin
gene
loop
length
virtu
chang
ala
arg
posit
predict
adopt
distinct
conform
type
present
loop
residu
antigen
rather
residu
type
loop
specif
somat
mutat
posit
asn
met
presum
promot
bind
possibl
predict
structur
larger
loop
tyrosin
locat
center
loop
may
play
analog
role
thu
crystal
structur
suggest
common
mechan
viru
neutral
nab
panel
make
contact
receptorbind
site
head
inhibit
cell
attach
rather
lock
fusion
peptid
helix
place
therebi
prevent
larg
structur
reorgan
requir
membran
data
point
event
occur
earli
step
infecti
process
although
rule
possibl
nab
act
later
stage
given
close
pack
molecul
surfac
matur
virion
might
restrict
earli
access
epitop
previous
publish
crystal
structur
hanab
complex
inhibit
membran
fusion
util
differ
mechan
prevent
conform
chang
crosslink
upper
surfac
adjac
subunit
next
examin
avail
ha
sequenc
total
public
influenza
sequenc
databas
supplementari
tabl
note
sequenc
epitop
nearli
alway
conserv
within
subtyp
inde
mani
epitop
residu
especi
highli
conserv
across
ha
subtyp
fig
high
sequenc
conserv
provid
rational
crossneutr
viru
clade
describ
prompt
us
test
antibodi
broader
rang
ha
subtyp
group
virus
contain
subtyp
classifi
cluster
fig
test
nab
bind
eight
member
cluster
includ
avian
well
common
human
influenza
subtyp
major
except
group
subtyp
addit
found
three
bound
cell
express
fulllength
two
differ
strain
includ
spanish
flu
cluster
subtyp
well
cluster
subtyp
two
strain
howev
none
bound
group
subtyp
supplementari
also
neutral
viru
infect
fig
microneutr
assay
also
neutral
influenza
virus
fig
howev
none
nab
neutral
group
virus
eg
fig
supplementari
fig
thu
nab
recogn
epitop
ha
conserv
among
clade
well
member
group
virus
final
demonstr
vivo
protect
efficaci
two
two
lethal
viral
strain
balbc
mous
model
use
protocol
studi
fig
abil
nab
recogn
group
cluster
virus
test
attribut
key
conserv
featur
nab
describ
combin
highli
conserv
pocket
ha
fig
epitop
may
divid
element
center
sequenc
ntermin
segment
fusion
peptid
residu
conserv
across
ha
subtyp
note
sidechain
posit
particip
bind
ii
downstream
segment
adopt
part
helix
residu
nearli
invari
signific
differ
thr
gln
chang
posit
untest
cluster
subtyp
lie
peripheri
epitop
make
one
long
hbond
simpl
model
suggest
plenti
space
accommod
larger
gln
sidechain
make
compar
hbond
iii
smaller
contribut
segment
chain
residu
loop
base
head
residu
comparison
epitop
known
crystal
structur
subtyp
three
group
two
group
show
adopt
two
distinct
structur
class
consist
phylogenet
fig
differ
aris
groupspecif
differ
locat
buri
residu
notabl
histidin
uniqu
group
uniqu
group
propos
trigger
phinduc
conform
differ
caus
sidechain
turn
group
subtyp
elimin
favor
bind
nab
panel
addit
four
six
group
subtyp
glycosyl
posit
peripheri
epitop
model
studi
predict
steric
clash
loop
data
shown
structur
differ
ration
observ
lack
bindingneutr
group
ha
subtyp
virus
remark
transform
fusogen
state
includ
repack
central
helic
three
protom
form
new
triplehel
bundl
residu
form
ntermin
cap
well
creation
ctermin
arm
extend
nterminu
new
straightforward
model
locat
epitop
residu
model
fusogen
state
see
supplementari
note
epitop
residu
fulli
expos
neutral
ph
structur
becom
either
part
new
hydrophob
bundl
core
make
network
hbond
ctermin
arm
element
stabil
new
bundl
ly
requir
adopt
two
entir
differ
conform
distinct
hydrophob
core
hbond
network
may
place
power
evolutionari
constraint
sequenc
helix
evidenc
almost
complet
lack
genet
drift
within
helix
among
ha
subtyp
test
hypothesi
attempt
select
neutral
escap
mutant
propag
viru
mdck
cell
presenc
nab
well
murin
ab
target
receptorbind
head
follow
three
vitro
passag
readili
isol
mutant
viru
resist
contrast
fail
identifi
virus
resist
experi
prove
escap
mutant
unimpair
viral
fit
never
aris
clearli
support
notion
pocket
refractori
epitop
head
notwithstand
mutant
aris
employ
vitro
approach
find
new
reactiv
nab
engin
exist
nab
even
broader
spectrum
prior
present
studi
vast
major
nab
isol
influenza
viru
target
receptorbind
head
lack
broad
crossneutr
activ
howev
murin
nab
term
posit
select
basi
crossneutr
properti
subtyp
subsequ
shown
neutral
group
supplementari
note
moreov
shown
block
membran
fusion
rather
cell
attach
protect
mice
viral
although
detail
mechan
report
compar
activ
found
show
similar
bind
toward
also
found
effici
compet
bind
vice
versa
supplementari
fig
furthermor
point
mutant
abrog
bind
ab
affect
bind
result
suggest
partial
overlap
epitop
mode
action
similar
manner
ha
present
antibodi
phage
display
librari
studi
seem
critic
success
sinc
similar
attempt
isol
broadli
nab
use
cellsurfac
express
ha
show
partial
success
ab
recogn
linear
note
repeatedli
isol
nab
util
vh
germlin
gene
huang
et
point
vh
gene
consist
encod
hydrophob
residu
tip
loop
inde
germlin
gene
encod
phe
posit
make
sever
critic
interact
moreov
type
loop
long
compact
predict
occur
human
germlin
gene
factor
may
explain
least
part
remark
abil
nab
deriv
germlin
gene
crossreact
viral
epitop
unusu
abil
bind
conserv
hydrophob
pocket
pocket
like
import
function
reason
often
cryptic
unactiv
state
antigen
exampl
predomin
gene
util
group
nab
rais
surfac
glycoprotein
pocket
part
conserv
coreceptor
bind
site
expos
transient
upon
bind
primari
receptor
similarli
antibodi
rais
hiv
trimer
innercor
fusion
protein
intermedi
util
hydrophob
tip
loop
insert
conserv
hydrophob
pocket
block
assembl
fusioncompet
vivo
b
cell
carri
gene
primari
mediat
innat
defens
hcv
infect
gener
antibodi
membran
fusion
glycoprotein
although
epitop
mode
action
determin
notabl
found
current
studi
germlin
suitabl
achiev
neutral
similar
manner
anoth
recent
exampl
nab
ebola
viru
surfac
glycoprotein
use
howev
common
abil
lock
viral
envelop
protein
nonfusogen
conform
offer
support
possibl
gener
strategi
broadspectrum
andor
potent
viral
neutral
recent
work
use
immunebas
phagedisplay
librari
gener
b
cell
popul
patient
surviv
infect
result
isol
three
human
nab
neutral
viral
strain
author
postul
reason
surviv
effect
humor
immun
respons
mediat
nabgener
b
cell
although
control
popul
studi
analysi
data
supplementari
note
indic
antibodi
also
deriv
germlin
gene
share
key
characterist
includ
metph
pair
tyrosin
tip
thu
would
appear
least
case
nonimmun
donor
librari
approach
gener
antibodi
characterist
similar
found
use
immunizeddonorbas
phagedisplay
librari
deriv
survivor
broadspectrum
nab
similar
identifi
studi
similarli
generatedexpand
success
round
influenza
infect
repeat
vaccin
known
supplementari
note
warrant
investig
unlik
epitop
provok
selftoler
mechan
via
autoantigen
supplementari
note
rather
hypothes
immunodomin
ab
respons
highlyexpos
globular
head
may
overwhelm
ab
respons
although
remain
possibl
immun
exclus
mechan
may
preclud
natur
ab
respons
epitop
surpris
mani
virus
highli
adept
keep
critic
conserv
determin
pathogenesi
cryptic
case
subunitbas
vaccin
util
properli
present
fragment
epitop
may
offer
distinct
advantag
wholevirusbas
approach
induct
broad
spectrum
nab
summari
use
vitro
methodolog
isol
famili
high
affin
broadspectrum
human
nab
ha
show
potent
vitro
vivo
efficaci
highli
pathogen
show
inhibit
postattach
fusion
process
recogn
highli
conserv
epitop
within
stem
region
ha
point
key
element
conform
chang
brought
close
apposit
initi
experi
suggest
region
recalcitr
gener
escap
mutant
prospect
use
passiv
immunotherapi
would
therefor
seem
excel
either
alon
combin
small
molecul
inhibitor
supplementari
note
final
structur
work
pinpoint
reason
group
bind
nab
describ
despit
surfac
sequenc
similar
form
structur
distinct
group
one
also
highli
conserv
therefor
may
amen
similar
pan
discoveri
approach
complex
form
incub
two
purifi
compon
excess
see
supplementari
method
isol
superdex
tb
buffer
peak
fraction
pool
concentr
mg
integr
trimer
examin
use
gel
filtrat
sdspage
crystal
grew
equilibr
equal
volum
protein
reservoir
solut
peg
wv
ethylen
glycol
wv
mm
tri
ph
use
hang
drop
vapor
diffus
techniqu
diffract
data
collect
crystal
flashfrozen
reservoir
buffer
stanford
synchrotron
radiat
laboratori
beamlin
set
wavelength
process
structur
solv
resolut
molecular
replac
phaser
use
structur
pdb
code
homolog
model
base
structur
sar
nab
pdb
code
start
model
asymmetr
unit
contain
two
trimer
three
molecul
per
trimer
refin
use
simul
anneal
manual
rebuild
final
map
high
qualiti
key
featur
cdr
loop
interfaci
residu
unambigu
consist
copi
final
model
includ
residu
independ
copi
residu
nacetyldglucosamin
unit
water
molecul
rfree
excel
geometri
assess
rampag
tabl
percentag
residu
favor
allow
outlier
region
respect
produc
recombin
trimer
ectodomain
crystal
studi
see
except
furin
coinfect
ensur
complet
activ
employ
ab
identifi
tworound
select
billion
member
human
scfv
phage
display
librari
recombin
trimer
immobil
immunotub
nunc
follow
elisa
screen
ten
uniqu
ab
identifi
sequenc
analysi
clone
clone
screen
virus
pfu
incub
scfvfc
three
differ
concentr
min
virusab
mixtur
dilut
logarithm
transfer
onto
mdck
cell
monolay
plate
incub
cell
wash
overlaid
agar
day
incub
overlay
discard
plaqu
visual
crystal
violet
stain
method
perform
describ
briefli
median
tissu
cultur
infecti
dose
viru
mix
equal
volum
twofold
serial
dilut
ab
stock
solut
tissu
cultur
plate
incub
indic
mdck
cell
cell
per
well
ad
plate
follow
incub
establish
endpoint
cell
monolay
wash
pb
fix
aceton
viral
antigen
detect
indirect
elisa
mab
influenza
np
accur
cell
incub
hiv
virus
ng
presenc
nab
control
mab
absenc
antibodi
pb
buffer
contain
wv
bsa
wv
incub
cell
spun
supernat
collect
test
level
use
captur
elisa
kit
nci
frederick
nih
quantifi
unbound
viru
cell
wash
twice
lyse
quantifi
cellbound
viru
use
method
hela
cell
confluent
sixwel
plate
transfect
plasmid
total
dna
per
well
use
lipofectamin
invitrogen
hour
transfect
cultur
medium
supplement
ml
control
mab
hour
cell
wash
incub
lowph
fusion
buffer
mm
nacl
mm
hepe
adjust
ph
min
cell
return
standard
cultur
medium
hour
final
fix
vv
glutaraldehyd
stain
wv
crystal
violet
photomicrograph
taken
magnif
femal
week
old
balbc
mice
use
experi
mice
weigh
day
viru
challeng
daili
week
bodi
weight
use
clinic
endpoint
mice
bodi
weight
loss
preinfect
valu
euthan
anim
studi
conduct
per
approv
institut
anim
care
use
committe
protocol
three
human
nab
control
human
mab
mg
mg
administ
group
mice
ip
inject
ml
volum
one
hour
mab
administr
two
group
mice
challeng
two
group
inocul
volum
per
mous
mice
observ
weigh
daili
twoweek
infect
analog
studi
perform
evalu
protect
efficaci
nab
apuerto
virus
experiment
design
recapitul
prophylaxi
studi
follow
except
twelv
group
mice
first
inocul
hour
infect
one
group
mice
receiv
ip
inject
mg
bodi
weight
one
three
nab
control
